Imaging biomarker studies

Overview

Support imaging biomarker studies in clinical trials.

Multi-Institution Study of DCE CT Imaging Biomarkers of Tumour Microvasculature in Metastatic Renal Cell Carcinoma Treated with Sunitinib– Reproducibility and Response Prediction

Lead principal investigator:
Dr. Masoom Haider (University Health Network/Sunnybrook Health Sciences Centre, OICR investigator, OICR Imaging Translation Platform participant)

Lead biomedical physicist:
Professor Ting-Y. Lee (Lawson Health Research Institute/Robarts Research Institute)

Lead medical oncologist:
Dr. Stephen Welch (London Regional Cancer Program)

Co-applicants:
Christina Maria Canil (medical oncologist, The Ottawa Hospital)
Najla Fasih (radiologist, The Ottawa Hospital)
Georg Bjarnason (medical oncologist, Sunnybrook Health Sciences Centre)
Laurent Milot (radiologist, Sunnybrook Health Sciences Centre)
Jennifer Knox (medical oncologist, University Health Network)
Patrick Rogalla (radiologist, University Health Network)

Objective:
To define the capability of DCE-CT as an imaging biomarker for monitoring treatment responses to anti-angiogenic therapy.

Goals:
Correlate:

• Early changes in microvasculature functional imaging biomarkers measured by DCE-CT with response by RECIST criteria.
• Microvascular imaging biomarkers with plasma concentration of plasma sunitinib concentration;
• Progression-free survival with microvascular imaging biomarkers.

• Microvascular parameters through CT standard operating procedure (SOP) combining CT RECIST assessment with DCE-CT.
• DCE-CT derived microvasculature related imaging biomarkers in the assessment of sunitinib treatment of RCC.
• Assess imaging biomarkers variability across two different platforms (64-& 320-slice CT).

A Pilot Study of Bold MRI and FLT-PET in Patients with Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy (IMPACT)

Co-applicants:
Kathy Pritchard (Sunnybrook Health Sciences Centre)
Dimitrios Vergidis (Thunder Bay Regional Health Sciences Centre)
Karen Gulenchyn (Nuclear Medicine Hamilton Health Sciences)
John Valliant (Centre for Probe Development and Commercialization, McMaster University)
Mike Noseworthy (BOLD MRI St Joseph’s Hospital Hamilton)

Objective:
Evaluation of imaging biomarkers (BOLD-MRI and FLT-PET) for accessing/monitoring treatment response.

Goals:

• Organize the infrastructure required to overcome the logistical challenges of integrating BOLD MRI and FLT-PET into clinical practice;
• Correlate BOLD MRI and FLT-PET and tumour markers with tumour histology pre-chemotherapy, with pathologic tumour response observed at mastectomy;
• Establish multi-centre SOPs and Q/A process for BOLD MRI and FLT-PET.

Imaging with ¹¹¹In-pertuzumab to Predict Response to Trastuzumab in HER2 Positive Metastatic Breast Cancer

Lead principal investigator:Mark Levine, McMaster University

Co-applicants:
Greg Pond (McMaster University)
Karen Gulenchyn (Hamilton Health Sciences)
Anita Bane (Hamilton Health Sciences)
Raymond Reilly (University of Toronto)
Philippe Bedard (University Health Network)
Marc Freeman (University Health Network)
Susan Done (University Health Network)
Sharon Nofech-Mozes (Sunnybrook Health Sciences Centre)
Scott Walker (Sunnybrook Health Sciences Centre)
Kathleen Pritchard (Sunnybrook Health Sciences Centre)
Lisa Ehrlich (Sunnybrook Health Sciences Centre)
Curtis Caldwell (Sunnybrook Health Sciences Centre)

Objective:
To improve the care of women with HER2-positive metastatic breast cancer (MBC) by using ¹¹¹In-pertuzumab imaging to predict who will respond to treatment with trastuzumab.

Goals:

• Study the safety, pharmacokinetics, radiation dosimetry, and tumour and normal tissue localization properties of ¹¹¹In-pertuzumab in patients with HER2-positive MBC who are beginning trastuzumab therapy combined with chemotherapy;
• Examine whether SPECT imaging with ¹¹¹In-pertuzumab can predict a clinical response to trastuzumab in patients with HER2-positive MBC who are beginning trastuzumab therapy combined with chemotherapy;
• In patients with HER2-positive MBC to conduct correlative biomarker studies that provide information on the binding of ¹¹¹In-PmAb to tumour and to explore whether certain biomarkers in the primary tumour are associated with clinical response to TmAb.